Biopharmaceutical company eFFECTOR Therapeutics has completed a $45 million Series A financing. Investors include U.S. Venture Partners, Abingworth, Novartis Venture Funds, SR One, Astellas Venture Management, Osage University Partners and Mission Bay Capital.

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $35.5 million in a Series E financing. The financing round included both current investors, Apple Tree Partners and Novartis Venture Funds, as well as undisclosed angel investors.

Thesan Pharmaceuticals has closed a $16 million Series A financing, co-led by Novo Ventures and Novartis Venture Funds. The company focuses on the development of novel approaches for the treatment of dermatological disorders.

Celladon Corp., a developer of treatments for cardiovascular diseases, has closed on $43 million in new capital. Pfizer Venture Investments led the round, which included investment from new backers Lundbeckfond Ventures, Novartis Venture Funds, H&Q Healthcare/Life Sciences Investors, and GBS Venture Partners. All previous investors participated in this round, including Enterprise Partners Venture Capital, Johnson [...]

Takeda Pharmaceutical Company, a listed, Japanese pharmaceutical research company, is buying venture-backed Intellikine Inc. Takeda will pay $190 million in cash, and up to $120 million in additional milestone payments. Intellikine was backed by at least $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Biopharma company Intellikine Inc. has sealed $4 million in new milestone payments as it begins two Phase 1 clinical trials of its drugs. The company, based in La Jolla, Calif., is backed by $41 million from venture investors including Abingworth, BiogenIdec, CMEA Capital, Fintech Global Capital, Novartis Venture Funds, Sofinnova Ventures and U.S. Venture Partners.

Advanced Animal Diagnostics, a developer of technologies to diagnose farm animal diseases, has closed on $11 million in Series B financing. Intersouth Partners led the round, which included participation from Novartis Venture Funds and other, unnamed investors. The company will use the financing to continue development of its diagnostic tests. Advanced Animal’s first on-farm product will focus on improving milk production and quality by controlling mastitis, an infection of the milk-producing gland of cows.